Search (Showing 1 - 10 of 21)
0.
Journal Entry
on June 14, 2016
Multi-billion dollar microcap opportunity hiding in a dark alley
Michael Bigger . Follow me on Twitter and StockTwits .
1.
Journal Entry
on August 4, 2015
"Harnessing the power of precision medicine to conquer Alzheimer's disease"
ProMIS!
This post was written by Michael Bigger in collaboration with Dr. Greg Kenausis . Kenausis' contribution is highlighted by using italics.
Ticker: PMN. ...
2.
Page
on January 25, 2016
Please use the Contact Us form or ping us here on twitter to add value added information to this page. We greatly appreciate your inputs as it helps us sharpen our thinking (pros, cons, insights, and so forth) about the company and it also helps other readers. This is a social experiment for now. ...
3.
Journal Entry
on October 15, 2016
A year ago, I made an investment in a tiny Canadian development stage biotech company: Promis Neurosciences (TSX:PMN). Promis focuses on novel, disease modifying therapies for the treatment of neurodegenerative diseases, particularly Alzheimer's and ALS.
What's fascinating about Promis is the Alzh ...
4.
Journal Entry
on April 23, 2017
Neurotrope (NTRP) will release its Bryostatin Phase 2b top line data this week (company’s guidance). The primary efficacy endpoint is based on Severe Impairment Battery Scale (SIB). Entry criteria was based on the MMSE score. Secondary efficacy endpoints were based on – Activities of Dai ...
5.
Journal Entry Follow-Up
on October 24, 2015
Alzheimer's, Light at the End of the Tunnel - ProMIS Webcast from ProMIS™ Neurosciences, Inc. on Vimeo .
6.
Journal Entry
on May 23, 2016
I am pleased to announce that on June 2nd at 3pm CST Scott Felsenthal at UnusualStocks will lead an investor call with management of ProMIS Neurosciences (PMN.TO). The call will be open to anyone interested in learning more about the company. The call will be limited to an hour.
...
7.
Journal Entry
on July 27, 2016
Promis Neurosciences presented two posters at the Alzheimer's Association International Conference held in Toronto today. Enjoy!
A Computational Method to Predict Disease-Specific Epitopes in Aβ, and Its Application to
Oligomer-Selective Antibodies for Alzheimer’s Immunotherapy
...
8.
Journal Entry
on October 11, 2015
"Harnessing the power of precision medicine to treat Alzheimer's and ALS"
ProMIS!
This post was written by Michael Bigger in collaboration with Dr. Greg Kenausis . Kenausis' contribution is highlighted by using italics. With the permision of the company, we are including non-confidential ...
9.
Journal Entry
on November 10, 2015
Here are the few things I am focused on. I really like the fact the company has a very small burn rate and it is also in a good position to unlock the potential of its IP.
Press Release .
As at September 30, 2015, the Company had working capital of $ 1,019,456. These funds are expected to fun ...